中国药物经济学
中國藥物經濟學
중국약물경제학
CHINA JOURNAL OF PHARMACEUTICAL ECONOMICS
2014年
4期
44-45
,共2页
瑞舒伐他汀%阿托伐他汀%冠心病%疗效
瑞舒伐他汀%阿託伐他汀%冠心病%療效
서서벌타정%아탁벌타정%관심병%료효
Rosuvastatin%Atorvastatin%Coronary heart disease%Curative effect
目的:采用对比法分析瑞舒伐他汀和阿托伐他汀对冠心病患者在非调脂、调脂方面及动脉粥样硬化逆转和安全性方面的疗效。方法选取2010年10月至2013年4月我院进行冠状动脉造影并证实为冠心病的患者160例,对其实施常规治疗。采取随机抽签分组的方式分为两组,治疗组口服瑞舒伐他汀片,对照组口服阿托伐他汀,疗程均为1年。对所有患者在治疗前、治疗后6、12个月的疗效、安全性进行比较。结果疗程结束后,组间比较发现治疗组各项均优于对照组,且组内比较也具有统计学意义。结论瑞舒伐他汀与阿托伐他汀两种药物均对动脉粥样硬化进程具有良好的逆转或延迟作用,能有效降低冠心病患者Hcy和血hs-CRP水平,改善患者血脂状况,但瑞舒伐他汀较阿托伐他汀的效果更加显著。
目的:採用對比法分析瑞舒伐他汀和阿託伐他汀對冠心病患者在非調脂、調脂方麵及動脈粥樣硬化逆轉和安全性方麵的療效。方法選取2010年10月至2013年4月我院進行冠狀動脈造影併證實為冠心病的患者160例,對其實施常規治療。採取隨機抽籤分組的方式分為兩組,治療組口服瑞舒伐他汀片,對照組口服阿託伐他汀,療程均為1年。對所有患者在治療前、治療後6、12箇月的療效、安全性進行比較。結果療程結束後,組間比較髮現治療組各項均優于對照組,且組內比較也具有統計學意義。結論瑞舒伐他汀與阿託伐他汀兩種藥物均對動脈粥樣硬化進程具有良好的逆轉或延遲作用,能有效降低冠心病患者Hcy和血hs-CRP水平,改善患者血脂狀況,但瑞舒伐他汀較阿託伐他汀的效果更加顯著。
목적:채용대비법분석서서벌타정화아탁벌타정대관심병환자재비조지、조지방면급동맥죽양경화역전화안전성방면적료효。방법선취2010년10월지2013년4월아원진행관상동맥조영병증실위관심병적환자160례,대기실시상규치료。채취수궤추첨분조적방식분위량조,치료조구복서서벌타정편,대조조구복아탁벌타정,료정균위1년。대소유환자재치료전、치료후6、12개월적료효、안전성진행비교。결과료정결속후,조간비교발현치료조각항균우우대조조,차조내비교야구유통계학의의。결론서서벌타정여아탁벌타정량충약물균대동맥죽양경화진정구유량호적역전혹연지작용,능유효강저관심병환자Hcy화혈hs-CRP수평,개선환자혈지상황,단서서벌타정교아탁벌타정적효과경가현저。
Objective With the method of comparison research and analysis of rosuvastatin and atorvastatin on curative effect of patients with coronary heart disease in non lipid, lipid and atherosclerosis reversal and security. Methods From 2010 October to 2013 April in our hospital for coronary angiography and confirmed 160 cases of coronary heart disease patients,the conventional treatment.Take the random way were divided into two groups, treatment group oral rosuvastatin tablets;the control group oral atorvastatin,treatment for 1 years.Al of the patients before and after the treatment,6,12 months curative effect,safety of comparison.Results After treatment,comparison between groups treatment group were better than the control group,and there was also significant within group comparison.Conclusion Rosuvastatin and atorvastatin two drugs have good reversal of atherosclerosis or delay action,can effectively reduce Hcy in patients with coronary heart disease and blood hs-CRP levels,improve blood lipid status of the patients,but rosuvastatin compared with atorvastatin more remarkable effect.